华兰疫苗(301207) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥34,222,695.90, a decrease of 76.36% compared to ¥144,762,101.26 in the same period last year[4] - Net profit attributable to shareholders was ¥38,589,463.38, down 58.93% from ¥93,967,811.66 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,157,030.81, reflecting a decline of 79.19% compared to ¥68,033,123.18 in the previous year[4] - Basic earnings per share were ¥0.0643, down 72.63% from ¥0.2349 year-on-year[4] - The total operating profit is 43,492,572.96, down from 105,903,077.92, indicating a significant decline in operational performance[26] - The total comprehensive income for the current period is 38,589,463.38, down from 93,967,811.66, a decrease of 58.92%[34] Cash Flow - The net cash flow from operating activities was ¥96,429,081.13, a decrease of 49.92% from ¥192,546,198.76 in the same quarter last year[4] - Cash flow from operating activities netted 96,429,081.13, a decrease of 50.06% from 192,546,198.76 in the previous period[27] - The total cash inflow from operating activities was 494,880,450.31, compared to 475,117,239.77 previously, showing a slight increase of 4.03%[27] - The total cash outflow from operating activities increased to 398,451,369.18, up from 282,571,041.01, reflecting a rise of 41.00%[27] - The net cash flow from investing activities was -111,857,051.36, an improvement from -363,764,238.06 in the previous period, indicating a reduction in cash outflow by approximately 69%[35] - The total cash and cash equivalents at the end of the period amounted to 623,990,420.48, compared to 427,323,825.23 at the end of the previous period, reflecting an increase of about 46%[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,809,176,465.58, a decrease of 2.33% from ¥7,995,318,297.21 at the end of the previous year[4] - The balance of trading financial assets rose to 2,397,529,136.99 from 1,598,524,035.48, marking an increase of 49.97%[31] - The total current assets increased to 5,313,164,810.94 from 5,226,815,305.37, representing a growth of 1.65%[31] - Total liabilities decreased to 1,501,964,758.85 from 1,732,226,370.79, a reduction of 13.29%[62] - Current liabilities decreased to 1,457,039,828.72 from 1,685,582,716.09, a decline of 13.51%[62] Equity and Shareholder Information - The company's total equity attributable to shareholders increased by 0.70% to ¥6,307,211,706.73 from ¥6,263,091,926.42 at the end of the previous year[4] - The total equity attributable to shareholders of the parent company increased to 6,307,211,706.73 from 6,263,091,926.42, marking a growth of approximately 0.7%[48] - The company reported a total of 18,051 common shareholders at the end of the reporting period[43] - The capital reserve increased to 2,920,707,131.72 from 2,915,176,814.79, showing a slight increase of about 0.2%[48] - The company’s retained earnings increased to 2,500,332,943.25 from 2,461,743,479.87, reflecting an increase of about 1.6%[48] Research and Development - The company's R&D expenses decreased by 34.39% to ¥19,022,504.10, down from ¥28,994,998.34 in the previous period[7] - Research and development expenses for the current period are 19,022,504.10, a decrease of 34.12% from 28,994,998.34 in the previous period[63] Other Financial Metrics - The company experienced a 61.41% increase in credit impairment losses, amounting to ¥33,913,652.37, compared to ¥21,010,630.96 in the previous year[7] - The income tax expense for the current period is 4,718,860.68, compared to 11,993,339.14 previously, a reduction of 60.66%[26] - The company reported a net investment income of 16,051,180.00, slightly down from 16,723,286.29 in the previous period[63]